Table 4.
References | Anesthetic Agent/Adjuvants | Sample Size | Effects |
---|---|---|---|
[34] | Desflurane | 45 | ET-1 ↓. May reduce the risk of acute cerebral vasospasm. |
[35] | Desflurane/Propofol | 102 | Less incidence of TCD-evident vasospasm with desflurane. |
[36] | Desflurane | 157 | Lower incidence of DCI. |
[37] | Sevoflurane/Desflurane | 390 | Lower incidence of angiographic vasospasm and DCI. |
[38] | Desflurane/Propofol | 70 | No effects on POCD at the time of discharge. |
[39] | Propofol | 45 | CGRP↓. May potentiate the risk of acute cerebral vasospasm. |
[41] | Propofol | 66 | No effect on cognition at time of hospital discharge. |
[40] | Ketamine, midazolam, propofol | 31 | Ketamine ↓ the occurrence of spreading depolarization’s, clusters of spreading depolarization’s and isoelectric spreading depolarizations. (NMDA ↓) Midazolam ↑ spreading depolarization clusters. (GABA ↓). Propofol ↓ clusters of spreading depolarizations. |
[42] | Ketamine | 65 | Lower incidence of non-procedural related infarctions probably through NMDA ↓, ↓ cortical spreading depolarization and vasodilation. |
[43] | Ketamine | 1 | NMDA ↓. Cortical spreading depolarization ↓. |
[44] | Ketamine | 8 | ↓ spreading depolarizations. |
[45] | Ketamine | 66 | ↓ spreading depolarizations. |
[50] | Dexmedetomidine | 161 | Favorable neurologic outcome at discharge as measured by mRS. |
[49] | Dexmedetomidine | 127 | No impact on vasospasm or clinical outcome at discharge as measured by mRS and GOS. |
[51] | flunitrazepam, midazolam, propofol | 29 | Associated with poor outcomes at 6 months after discharge as measured by GOS. |
↑ = Activation/Increase/elevation, ↓ = Inhibition/blockade/decrease, ET-1 = endothelin, TCD = transcranial Doppler, CGRP = calcitonin gene- related peptide, GABA = Gamma- aminobutyric acid, NMDA = N-methyl- D- Aspartate, POCD = post-operative cognitive dysfunction, mRS = modified Rankin scale, GOS = Glasgow outcome scale.